About the Hospital Sector

India’s hospital sector has been witnessing structural growth driven by rising healthcare awareness, increasing insurance penetration, and expansion of organized healthcare chains. Large hospital players are now focusing on capacity expansion and premium service offerings.

HSBC Sector Outlook

🟢 Q4FY26 expected to remain steady

🟢 Elective procedures seeing recovery

🟡 Capex expansion remains key focus

🟡 New unit additions may impact margins temporarily

HSBC believes the sector is entering a stable growth phase, supported by improving patient inflows and strong demand visibility.

Top Picks and Ratings

🟢 Apollo Hospitals: Buy | Target ₹9,000 (raised from ₹8,750)

🟢 Max Healthcare: Buy | Target ₹1,125

🟢 Aster DM Healthcare: Buy | Target ₹755 (raised from ₹635)

🟢 KIMS: Buy | Target ₹780 (raised from ₹750)

🟢 Rainbow Children’s: Buy | Target ₹1,400

🟡 Global Health: Hold | Target ₹1,120 (raised from ₹1,100)

🔴 Narayana Hrudayalaya: Reduce | Target ₹1,630 (raised from ₹1,620)

Key Growth Drivers

🟢 Rising elective surgeries post normalization

🟢 Expansion of hospital networks

🟢 Increasing demand for premium healthcare services

Elective procedures are a key revenue driver for hospitals, and their recovery signals normalization of healthcare demand after disruptions.

Margin Outlook

🟡 Capex-led expansion may pressure margins

🟢 Mature hospitals continue to deliver stable profitability

New hospital units typically take time to reach optimal utilization, which may temporarily impact margins, but long-term growth remains intact.

Sector Strategy Insight

🟢 Preference for scale players like Apollo Hospitals

🟢 Strong execution and brand advantage matter

🟡 Stock selection becomes critical at current valuations

HSBC continues to prefer large, well-managed hospital chains with strong occupancy rates and execution track record.

About Anthem Bio

Anthem Biosciences operates in the CRDMO (Contract Research, Development, and Manufacturing Organization) space, offering integrated services across drug discovery, development, and manufacturing. The company benefits from increasing global outsourcing trends in the pharmaceutical and biotech industries.

Citi View on Anthem Bio

🟢 Recommendation: Buy

🟢 Target Price: ₹870

Citi highlights Anthem Bio as a high-growth player within the CRDMO segment, driven by strong execution and expanding capabilities.

Growth Drivers

🟢 Accelerated growth expected in CRDMO segment

🟢 Increasing outsourcing by global pharma companies

🟢 Strong demand visibility over FY27–FY28

The shift towards outsourcing complex drug development processes is creating long-term tailwinds for companies like Anthem Bio.

Platform Advantage

🟢 Differentiated multi-modality platform

🟢 Integrated offerings from research to manufacturing

Anthem Bio’s integrated model provides end-to-end solutions, making it a preferred partner for global pharmaceutical clients and enhancing revenue visibility.

Business Momentum

🟢 Strong growth in commercial molecules

🟢 Scaling operations across value chain

Growth in commercial-stage molecules indicates a transition towards higher-margin business segments, supporting long-term profitability.

Strategic Outlook

🟢 High visibility of earnings growth

🟢 Beneficiary of global pharma outsourcing trend

🟢 Positioned in a structurally growing industry

The CRDMO space is witnessing structural demand growth, and Anthem Bio is well-positioned to capitalize on this opportunity over the next few years.

About Asian Paints

Asian Paints is India’s leading decorative paints company with a dominant distribution network, strong brand equity, and consistent market leadership. It has built a robust presence across urban and rural markets, making it one of the most reliable consumption-driven stocks in the country.

Macquarie View

🟢 Recommendation: Outperform

🟢 Target Price: ₹2,900

Macquarie maintains a positive outlook on Asian Paints, emphasizing pricing power and industry resilience despite rising competition concerns.

Price Hike Strategy

🟢 Second round of price hikes implemented

🟢 Total cumulative hikes reach ~12%

🟢 Earlier 6–8% hike already matched by peers

The company continues to demonstrate strong pricing power, which is a key indicator of industry leadership and brand strength.

Industry Dynamics

🟢 Price hikes being replicated across industry

🟢 Limited structural impact from new competition

Macquarie believes that fears around margin pressure due to new entrants may be overstated, as the industry has demonstrated the ability to pass on cost increases effectively.

Margin Outlook

🟡 Input cost inflation remains a short-term concern

🟢 Price hikes expected to offset margin pressure

While raw material costs may create temporary pressure, the pricing flexibility of leading players like Asian Paints helps maintain long-term margin stability.

Strategic Insight

🟢 Strong brand-driven demand

🟢 Industry leader with pricing control

🟢 Ability to sustain profitability through cycles

Asian Paints continues to stand out as a consumption-led compounder with strong fundamentals and industry leadership advantages.

About UltraTech Cement

UltraTech Cement is India’s largest cement manufacturer and part of the Aditya Birla Group. The company has built a dominant position through a combination of organic expansion and strategic acquisitions, making it a key beneficiary of India’s long-term infrastructure and housing growth story.

Jefferies View on UltraTech

🟢 Recommendation: Buy

🟢 Target Price: ₹14,025

🟢 Positioned as a long-term infrastructure proxy

Jefferies maintains a positive stance on UltraTech, highlighting its scale, operational efficiency, and strong positioning in India’s growth cycle.

Key Growth Highlights

🟢 Crossed 200 MTPA capacity milestone

🟢 Largest cement producer outside China

🟢 4-decade journey of consistent growth

🟢 Balanced mix of organic expansion and M&A

The company’s ability to scale operations while maintaining efficiency gives it a significant competitive advantage in a cyclical sector like cement.

Operational Strength

🟢 Higher capacity utilisation vs industry

🟢 ~30% market share in volumes

🟢 Industry-leading EBITDA per unit

🟢 Scale helps absorb cyclicality

UltraTech’s leadership position allows it to operate more efficiently than peers, resulting in better margins even during weaker demand phases.

Valuation Perspective

🟡 Valuations appear premium vs global peers

🟢 Strong growth visibility supports premium

While the stock trades at higher multiples, investors are paying for consistency, leadership, and long-term growth potential linked to India’s infrastructure push.

Strategic Outlook

🟢 Clean large-cap infrastructure play

🟢 Direct beneficiary of capex cycle

🟢 Strong execution track record

UltraTech continues to stand out as a high-quality compounder within the cement sector, backed by strong execution and scale advantages.

About the Market Setup

Markets are expected to open on a positive note supported by global cues, easing crude prices, and optimism around US–Iran talks. However, FIIs turning sellers and geopolitical uncertainty may keep volatility elevated.

Key Positive Stocks

🟢 Vedanta: Demerger approval (value unlocking trigger)

🟢 FACT, RCF, National Fertilizers: Strong core sector output

🟢 PNB Housing Finance: Q4 PAT beat driven by recoveries

🟢 ONGC, Oil India: Elevated crude supports earnings

🟢 Banking Stocks: RBI forex circular withdrawal

🟢 Oberoi Realty: Strong booking growth (+96% YoY)

🟢 E2E Network: Turnaround quarter

🟢 JSW Steel: JV with POSCO

🟢 Interarch Building: ₹80 Cr order win

🟢 TVS Motor: Partnership with Hyundai

🟢 Hindustan Copper: ₹7,189 Cr capex plan

🟢 Suzlon Energy: Pact with GS E&C

Other Stocks in Focus

🟢 TCS: MoU with NAVER Corp

🟢 Associated Alcohol: Acquisition of SDF Industries

🟢 Balrampur Chini, SPML Infra: Fund raise meetings

🟢 Apeejay Hotels: Expansion in Ujjain & Ayodhya

🟢 Carysil: Capacity expansion

🟢 Rolex Rings: Buyback meeting

🟢 AU Small Finance Bank: Fund raise plans

🟢 Ravindra Energy: MoU with Drivn

🟢 Groww: Brokerage upgrades

🟢 PhysicsWallah: JP Morgan overweight rating

Negative Stock Trigger

🔴 PDS: FIR filed over alleged misconduct

Global Market Cues

🟢 GIFT Nifty: Positive संकेत (+0.31%)

🟢 Nikkei: +1.12%

🟢 Hang Seng: +0.76%

🟢 Shanghai: +0.75%

🟡 US Markets: Mixed

Global sentiment remains cautiously positive, driven by optimism around ceasefire discussions and stability in crude prices.

Key Market Themes

🟢 Value unlocking (Vedanta)

🟢 Commodity strength (Oil, Metals)

🟢 Earnings momentum (Realty, NBFC, Tech)

🟡 Fund raising activity across sectors

🔴 FII selling pressure emerging

About the Demerger

Vedanta has approved a major demerger aimed at unlocking value by separating its businesses into independent listed entities. This restructuring is expected to improve transparency and allow each segment to attract focused investments.

Key Dates You Must Track

📅 Record Date: May 1, 2026

📅 Last Day to Buy Shares: April 29, 2026

📅 May 1: Market Holiday (important adjustment)

Since May 1 is a market holiday, investors must ensure shares are bought before April 29 to be eligible for the demerger benefits.

Demerger Ratio Explained

📊 For every 1 share of Vedanta Ltd:

🟢 You will receive 1 share each in 4 new companies

This effectively means investors will hold shares in multiple focused businesses instead of one conglomerate structure.

New Companies After Demerger

🏭 Vedanta Aluminium

🛢️ Vedanta Oil & Gas

⚡ Vedanta Power

⛓️ Vedanta Steel and Ferrous Materials

🏢 Vedanta Ltd (existing entity)

Post demerger, Vedanta will operate as five separate listed companies, each representing a specific business vertical.

Why This Demerger Matters

🟢 Value unlocking for shareholders

🟢 Better business focus for each segment

🟢 Potential re-rating of individual companies

Conglomerates often trade at a discount. Demergers help reveal the true value of each business, which can benefit long-term investors.

Important Investor Insight

🟡 Price may adjust after record date

🟢 Total value remains intact (value redistribution)

🔴 Short-term volatility likely

After demerger, the stock price of Vedanta Ltd will adjust downward to reflect separation of businesses, but investors receive equivalent value through new shares.